[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guang'anmen Hospital of China Academy of Chinese Medical Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":602},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,47,71,97,136,161,184,211,235,257,281,302,322,339,358,375,396,418,440,464,489,514,532,557,579],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641848","phase-2-taic-folfox-for-locally-advanced-ggeja-100641848",false,"NCT07655024","TAIC FOLFOX for Locally Advanced G\u002FGEJA","FOLFOX-Based Transarterial Infusion Chemotherapy for Locally Advanced Gastric Cancer and Gastroesophageal Junction Adenocarcinoma: Protocol of an Open-Label, Multicentre, Single-arm, Phase Ⅱ Trial","TFLAG","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Pathologically diagnosed with G\u002FGEJA\n* Confirmed by the surgeon as initially unresectable advanced G\u002FGEJC\n* Contraindicated to surgery due to frailty or comorbidities\n* Expected survival period ≥ 3 months\n\nExclusion Criteria:\n\n* Primary malignant tumors\n* Gastrointestinal obstruction caused by lesions in the distal stomach, duodenum, pancreas or other organs\n* Acute infection, severe liver or kidney dysfunction or coagulation disorder\n* Allergic to the drugs or with mental disorders","ALL","18 Years",{"count":21,"type":22},31,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Gastric cancer is the fifth most common malignancy worldwide in terms of both incidence and mortality. The majority of cases are diagnosed at advanced stage-often presenting with severe complications such as malignant stricture, obstruction, bleeding, and cancer-related malnutrition-which impinge on quality of life and survival outcomes. For patients with unresectable or metastatic gastric cancer and gastroesophageal junction adenocarcinoma (G\u002FGEJA), first-line systemic therapy remains predominantly platinum- and fluoropyrimidine-based combination chemotherapy, and targeted agents or immunotherapy can be added based on the expression of biomarkers. Under this standard approach, the median overall survival (mOS) for localized unresectable G\u002FGEJA is approximately 14-20 months. For metastatic G\u002FGEJA, the prognosis remains poor with an mOS of less than 1 year, despite the proven efficacy of chemotherapeutic agents. Moreover, up to 25% of cancer survivors report a significant decline in quality of life due to gastrointestinal symptoms during, soon after, or many years after treatment.\n\nInterventional oncology approaches-including trans-arterial infusion chemotherapy (TAIC), embolization (TAE), and chemoembolization (TACE)-represent promising locoregional therapeutic strategies. TAIC allows for the direct delivery of cytotoxic agents into the tumor-feeding arteries, thereby maximizing intra-tumoral drug concentration. As one of the most well-recognized applications, hepatic arterial infusion chemotherapy (HAIC) has been demonstrated in liver cancer by elevating local drug exposure, markedly enhancing antitumor efficacy while minimizing systemic adverse effects. Moreover, chemotherapeutic agents may exert secondary systemic activity against clinically or subclinically disseminated metastases upon systemic circulation, contributing to a sustained \"secondary chemotherapy\" effect. Owing to its favorable safety profile and preserved antitumor activity, TAIC is particularly suited for frail or elderly patients who are ineligible for surgery or conventional systemic chemotherapy.\n\nGiven the persistent limitations of current therapeutic paradigms, the feasibility and safety of trans-arterial therapy in the treatment of anti-tumor, hemostasis and obstruction relief for locally advanced G\u002FGEJC remains urgent. The present study aimed to assess the efficacy and safety of TAIC for locally advanced G\u002FGEJA.",[28,29],"Gastric Cancer (Diagnosis)","Gastroesophageal Junction Adenocarcinoma",[31,32,33],"Unresectable Gastric cancer","Esophagogastric junction adenocarcinoma","Transarterial infusion chemotherapy","RECRUITING","2026-06-15",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":38},"2025-11-01",{"date":42,"type":22},"2028-12-01",{"name":44,"class":45},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":46},"100599231","the-effect-of-perioperative-transcutaneous-electrical-acupoint-stimulation-combined-with-traditional-chinese-medicine-on-gastrointestinal-function-recovery-in-patients-undergoing-abdominal-surgery-100599231","NCT07081802","The Effect of Perioperative Transcutaneous Electrical Acupoint Stimulation Combined With Traditional Chinese Medicine on Gastrointestinal Function Recovery in Patients Undergoing Abdominal Surgery","the Effect of Perioperative Transcutaneous Electrical Acupoint Stimulation Combined With Traditional Chinese Medicine on Gastrointestinal Function Recovery in Abdominal Surgery Patients","Inclusion Criteria:\n\n* Patients aged \\>18 years with no severe preoperative gastrointestinal dysfunction (e.g., no chronic gastrointestinal diseases such as long-term constipation or diarrhea).\n* Scheduled abdominal Grade IV surgeries (limited to liver, gallbladder, pancreas, stomach, or intestinal procedures) performed via open or laparoscopic approach.\n* Preoperative American Society of Anesthesiologists (ASA) Physical Status Classification of I-III.\n* Patients and their families fully understand the study's purpose, methods, potential risks\u002Fbenefits, and provide signed informed consent.\n\nExclusion Criteria:\n\n* Comorbid severe systemic diseases.\n* Local skin abnormalities at acupoints (e.g.,broken skin, infection, allergies, or scarring).\n* Preoperative long-term use (\\>1 month) of gastrointestinal motility-affecting drugs (e.g., mosapride, domperidone) that cannot be discontinued, or allergies to TCM components\u002Felectrode materials.\n* Psychiatric disorders or cognitive impairment rendering patients unable to comply with the study.\n\nElimination Criteria:\n\n* Non-compliance with treatment protocols (e.g., receiving \\\u003C80% of planned sessions).\n* Significant missing data.\n* Occurrence of severe adverse events unrelated to the study intervention.","80 Years",{"count":56,"type":22},148,[58],"NA","Protocol Summary Project Name:Effect of Perioperative TEAS Combined with TCM on Gastrointestinal Function Recovery in Abdominal Surgery Patients Research Objective:To evaluate the impact of perioperative TEAS combined with TCM on postoperative gastrointestinal function, pain, adverse reactions, hospital stay, and complications, as well as its safety, aiming to enrich the ERAS and prehabilitation theory and promote the integration of TCM in surgical practice.\n\nResearch Design:Prospective, randomized, open-label trial involving 148 abdominal surgery patients (Grade IV surgeries) randomly assigned 1:1 to the experimental group (TCM + TEAS + prehabilitation + ERAS) or the control group (prehabilitation + ERAS).\n\nTotal Cases:148 Case Selection\n\nInclusion Criteria:\n\n1. Age 18-80, no severe gastrointestinal dysfunction;\n2. Elective abdominal Grade IV surgeries (pancreas or colorectall surgeries) via open or laparoscopic methods;\n3. Preoperative ASA classification I-III;\n4. Signed informed consent.\n\nExclusion Criteria:\n\nSevere comorbidities, skin abnormalities at acupoints, long-term use of gastrointestinal motility drugs, or other factors affecting the trial.\n\nElimination Criteria:\n\nPoor compliance, significant missing data, or severe adverse events unrelated to the intervention.\n\nTreatment Plan TEAS combined with TCM from the day of surgery to postoperative day 4, alongside prehabilitation and ERAS.\n\nEfficacy Evaluation\n\nPrimary Outcomes:\n\nTime to first flatus and defecation.\n\nSecondary Outcomes:\n\nPostoperative hospital stay, time to tolerate semi-liquid\u002Fsolid food, nausea\u002Fvomiting, pain, bloating, first ambulation, 30-day readmission rate, WBC\u002FCRP levels, and gastrin levels.\n\nSafety Evaluation: Any adverse events. Statistical Methods Continuous variables expressed as mean (SD) or median (IQR); independent t-test for normal distributions. Categorical variables summarized as frequencies\u002Fpercentages, analyzed using χ² or Fisher's exact test. Group differences reported as 95% CI and two-sided P-values (P \\\u003C 0.05 significant). Preset subgroup analyses by surgery type and frailty.",[61,62],"ERAS","Traditional Chinese Medication (TCM)","2026-05-30",{"date":65,"type":38},"2026-06-02",{"date":67,"type":38},"2025-09-01",{"date":69,"type":22},"2026-09-28",{"name":44,"class":45},{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":78,"minAge":19,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100617863","acupuncture-for-erectile-dysfunction-100617863","NCT07324148","Acupuncture for Erectile Dysfunction","Acupuncture for Erectile Dysfunction Among Patients With Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome: a Clinical Trial","Inclusion Criteria:\n\n* Conforms to the diagnosis of CP\u002FCPPS and pED at the same time;\n* Aged between 18-50 years old;\n* 8≤IIEF-5 score≤21\n* Have a fixed sexual partner and a regular sexual intercourse of ≥1 time\u002Fweek during treatment period;\n* Voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with drug-induced or organic ED.\n* The existence of lesions that may affect erectile function, such as penile cancer, penile sclerosis, penile anatomical deformity, testicular cancer, urinary system stones or neuropathy, etc.\n* History of trauma or surgery in pelvic region.\n* Patients with hypogonadism.\n* Usage of drugs or therapies that relieve CP\u002FCPPS or ED symptoms in the previous 1 month.\n* Have received hormonal or psychiatric drugs in the previous 3 months.\n* Bladder outlet obstruction, overactive bladder, neurogenic bladder, interstitial cystitis, glandular cystitis, sexually transmitted diseases, bladder tumors, prostate cancer, penile cancer, penile stone, other types of prostatitis.\n* With a residual urine ≥100ml.\n* Symptomatic urinary tract infection.\n* Diseases affecting the function of the lower urethra, such as multiple sclerosis, senile dementia, Parkinson's disease, spinal cord injury, caua equina nerve injury, stroke and multisystem atrophy, etc.\n* Severe diseases in heart, lung, brain, liver, kidney and hematopoietic system , mental illness and obvious cognitive function disorders.\n* Patients with poor compliance","MALE","50 Years",{"count":81,"type":22},100,[58],"Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS) is a prevalent chronic urological disease. CP\u002FCPPS severely impacts patients' quality of life. It is characterized by recurrent pelvic floor pain, lower urinary tract symptoms, and often accompanied by psychological issues and sexual dysfunction (duration ≥3 months, no confirmed infection\u002Fpathology).\n\nThe investigators have completed a large-sample, multi-center randomized controlled trial (RCT) involving 440 patients with CP\u002FCPPS before. The clinical trial confirmed the sustained efficacy of acupuncture for the symptoms of pain, lower urinary tract symptoms, and anxiety and depression among patients with CP\u002FCPPS. However, the trial revealed no significant improvements in sexual dysfunction in the acupuncture group compared to the sham acupuncture group after 8 weeks of treatment.To address this limitation, the current study is designed, which aims to optimize the clinical acupuncture protocol for CP\u002FCPPS and evaluate whether it can enhance outcomes for psychogenic erectile dysfunction (ED) associated. Additionally, mass cytometry and liquid suspension chip technology will be used to explore systemic and local immune mechanisms underlying acupuncture's effects for CP\u002FCPPS. Functional magnetic resonance imaging (fMRI) and metabolomics will be integrated to analyze patients' systemic states from central nervous system and metabolic perspectives, comprehensively elucidating the multi-dimensional mechanisms by which acupuncture alleviates CP\u002FCPPS.",[85,86,87],"Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS)","Erectile Dysfunctions","Acupuncture","NOT_YET_RECRUITING","2026-01-06",{"date":91,"type":38},"2026-01-08",{"date":93,"type":22},"2026-01-01",{"date":95,"type":22},"2028-06-30",{"name":44,"class":45},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":123,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":46},"100616152","generative-ai-impact-on-rheumatoid-arthritis-complications-diagnosis-100616152","NCT07301892","Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis","Impact of Generative Artificial Intelligence on Diagnosing Rheumatoid Arthritis Complications","Inclusion Criteria:\n\n* Patients with an initial diagnosis of rheumatoid arthritis (RA).\n* All real-world RA inpatients admitted to our department.\n* Admission occurring within the real-world data study period.\n\nExclusion Criteria:\n\n* Patients subsequently confirmed not to have RA during the study.",{"count":81,"type":22},"OBSERVATIONAL","Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.",[108,109,110,111,112,113,114,115,116,117,118,119,120,121,122],"Rheumatoid Arthritis (RA","Osteoporosis","Osteoarthritis","Interstitial Lung Disease","Thyroid Diseases","Cardiovascular Diseases","Pulmonary Complications","Sjogren's Syndrome","Liver Disorders","Renal Lesions","Vasculitis","Amyloidosis","Peripheral Neuropathy","Thrombosis","RA Complications",[124,125,126,127],"Rheumatoid Arthritis","generative AI","large language model","Rheumatoid arthritis complications","2025-12-22",{"date":130,"type":38},"2025-12-24",{"date":132,"type":38},"2025-10-01",{"date":134,"type":22},"2026-06",{"name":44,"class":45},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":143,"sex":144,"minAge":19,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":46},"100607073","acupuncture-for-anxietydepression-in-patients-with-breast-cancer-100607073","NCT07183813","Acupuncture for Anxiety\u002FDepression in Patients With Breast Cancer","Effects of Acupuncture for Anxiety and\u002For Depression Among Patients With Breast Cancer","Inclusion Criteria:\n\n1. Female, aged 18 to 70 years old;\n2. Meeting the diagnostic criteria for breast cancer and at TMN I-III;\n3. Having completed specialized active treatment for at least one month;\n4. With an ECOG score of 0-2;\n5. Mild to moderate anxiety and\u002For depression;\n6. Voluntarily joining this study and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Starting to take or change the regimen of anti-anxiety and\u002For -depression disorder medication within one month before enrolment;\n2. Received psychological intervention or physical therapy one month before enrolment or planning to use in the next 5 months;\n3. With diagnosis of anxiety and\u002For depression disorder prior to the diagnosis of breast cancer;\n4. Patients with suicidal tendencies, bipolar disorder and psychotic symptoms;\n5. Patients with severe anxiety and\u002For depression；\n6. Patients received acupuncture treatment within one month before enrolment;\n7. Participating in other clinical studies on the treatment of anxiety and\u002For depression;\n8. Combined with severe underlying diseases;\n9. Patients with severe skin ulcers;\n10. Pregnant or lactating patients;\n11. Poor compliance.",true,"FEMALE","70 Years",{"count":147,"type":22},360,[58],"The aim of this study is to evaluate the effects and safety of acupuncture on anxiety and\u002For depression among patients with breast cancer.",[151,152,87],"Anxiety Depression","Breast Cancer","2025-09-19",{"date":155,"type":38},"2025-09-24",{"date":157,"type":22},"2025-09-15",{"date":159,"type":22},"2026-12-30",{"name":44,"class":45},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100604493","effectiveness-of-acupuncture-for-cervical-spondylotic-radiculopathy-100604493","NCT07150234","Effectiveness of Acupuncture for Cervical Spondylotic Radiculopathy","Inclusion Criteria:\n\n1. Age is 18-75 years old;\n2. Patients meets the diagnostic criteria of cervical spondylotic radiculopathy and the discomfort such as pain and numbness only radiates to one upper limb (unilateral);\n3. NRS score of the average 24h arm pain\u002Fnumbness in the last week was ≥4;\n4. The course of disease is ≥6 weeks;\n5. Patients voluntarily participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Those with tumors, connective tissue diseases, rheumatism, spinal cord diseases, fractures, vertebral dislocation, metabolic and endocrine diseases (paget's disease, osteoporosis), other neuropathy (peripheral neuropathy, amyotrophic lateral sclerosis, transverse myelitis, Guillain-Barre syndrome, brachial plexus neuropathy), vascular related diseases (carotid artery dysfunction, arteriovenous fistula or deformity), inflammation(rheumatoid arthritis, inflammatory arthritis, ankylosing spondylitis) and infectious diseases (osteomyelitis, abscess, discitis, Lyme disease, herpes zoster, meningitis), etc.\n2. Those with diseases such as scapulohumeral periarthritis, thoracic outlet syndrome, tennis elbow, carpal tunnel syndrome, etc. that cause upper limb pain or discomfort;\n3. Those with cervical spondylotic radiculopathy whose condition is in a rapidly progressive stage;\n4. Those received systematic comprehensive conservative treatment fails for three months, the conservative treatment includes physical therapy (fixation, traction, manipulation, exercise, ultrasound and infrared), drugs (ibuprofen, nonsteroidal anti-inflammatory drugs, gabapentin, pregabalin, antidepressants, etc.) and nerve block;\n5. Those with ankylosis of vertebral joints;\n6. Those neurological impairment (such as muscular atrophy and sensory disturbance);\n7. Those with congenital abnormality of cervical vertebra;\n8. Those with head and neck injuries and surgical history;\n9. Those with long-term use of analgesics, muscle relaxants, hormones, or other pain more severe than neck pain;\n10. Those with mental illness such as depression, anxiety, suicidal tendency, cognitive dysfunction or language disorder;\n11. Those who received acupuncture treatment one week before joining the group;\n12. Those who with drug dependence;\n13. Those who with serious heart, liver, kidney, hematopoietic system, coagulation system, autoimmune system diseases, poorly controlled hypertension, diabetes, active infection, infectious diseases, severe malnutrition in the whole body, malignant tumor or serious diseases at the end stage;\n14. Those who are pregnant or planning pregnancy, lactating and postpartum ≤12 months within one year;\n15. Those who are metal allergy or serious needle fear;\n16. Those with skin ulcer, damage and scar at selected acupoints;\n17. Those who have received other clinical study within 90 days prior to randomization;\n18. Pending litigation or industrial injury compensation related to neck pain;\n19. Those who are unable to communicate in Mandarin or read Chinese.","75 Years",{"count":169,"type":22},168,[58],"This study will be an evaluation of the efficacy and safety of acupuncture for cervical spondylotic radiculopathy. The main questions it aims to answer are 1. Does acupuncture improve the pain intensity among patients with cervical spondylotic radiculopathy? 2. Does acupuncture treat cervical spondylotic radiculopathy safely? Researchers will compare acupuncture to sham acupuncture to see if acupuncture could improve symptoms among patients with cervical spondylotic radiculopathy. Experimental and control groups will be treated with 6 weeks of acupuncture or sham-acupuncture respectively. Patients were followed up at 1 month, 3 months, 6 months after treatment to record outcome, any disease progression, adverse events, and so on.",[173],"Cervical Spondylotic Radiculopathy",[175],"cervical spondylotic radiculopathy","2025-08-24",{"date":178,"type":38},"2025-09-02",{"date":180,"type":22},"2025-09-10",{"date":182,"type":22},"2028-09-30",{"name":44,"class":45},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":200,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":46},"100543711","acupuncture-for-prediabetes-with-combined-obesity-100543711","NCT06359418","Acupuncture for Prediabetes With Combined Obesity","Acupuncture for Prediabetes With Combined Obesity: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n\\-\n\nSubjects are eligible to be included in the trial only if all of the following criteria apply:\n\n1. Simultaneously meeting the diagnostic criteria for both general obesity, abdominal obesity, and prediabetes;\n2. Aged 18-64 years old;\n3. Informed consent obtained before any trial-related activities.\n\nExclusion Criteria:\n\n\\-\n\nSubjects are excluded from the trial if any of the following criteria apply:\n\n1. Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established Polycystic Ovary Syndrome);\n2. impaired glucose regulation due to hyperthyroidism, endocrine tumors and extensive liver damage;\n3. Diagnosis of type 1 or type 2 diabetes per the judgment of the investigator;\n4. Current or history of treatment with medications that may cause significant weight gain, within 3 months prior to screening, including systemic corticosteroids (except for a short course of treatment, i.e. 7-10 days), antidepressants, antipsychotic, mood stabilizers, antiepileptic and hormone contraceptive;\n5. History of pancreatitis or pancreatectomy;\n6. Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device;\n7. Current participation (or within the last month) in an organized weight reduction program or currently using or used medication for obesity or hyperglycemia within 3 months before screening: liraglutide, exenatide, pramlintide, orlistat, topiramate, phenteremine, or metformin (either by prescription or as part of a clinical trial);\n8. A self-reported change in body weight \\>5 kg within 3 months before screening irrespective of medical records;\n9. Serious medical conditions (including but not limited to ongoing renal or hepatic insufficiency, congestive heart failure, myocardial infarction, stroke, hematopoietic system diseases, progressive malignant tumor or other serious consumptive diseases); history of angina pectoris, transient ischemic attack, claudication, or acute limb ischemia within the past 6 months prior to screening;\n10. Serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious personality disorder, (e.g. borderline or antisocial), current severe major depressive disorder, recent (previous 6 months) suicide attempt or current active suicidal ideation, recent hospitalization due to psychiatric illness;\n11. Skin infection, blood coagulation disorders and other conditions that are not suitable for acupuncture;\n12. Metal allergies or severe fear of needles;\n13. Pregnant or breast-feeding women or planning to become pregnant during the study period;\n14. Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol.","64 Years",{"count":193,"type":22},260,[58],"The clinical trial aims to evaluate the efficacy and safety of acupuncture in reducing weight and waist circumference while modulating glucose and lipid metabolism in Prediabetes with Combined Obesity.",[197,198,199],"Obesity","Abdominal Obesity","PreDiabetes",[201,202,197,198,199],"acupuncture","randomized controlled trial","2025-08-16",{"date":205,"type":38},"2025-08-22",{"date":207,"type":38},"2025-03-01",{"date":209,"type":22},"2028-04-01",{"name":44,"class":45},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":144,"minAge":19,"maxAge":79,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":226,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":46},"100544108","electroacupuncture-for-dysmenorrhea-secondary-to-adenomyosis-100544108","NCT06364592","Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis","Effect of Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis: an Exploratory Pilot Study","Inclusion Criteria:\n\n* Meeting the diagnosis criteria of dysmenorrhea secondary to adenomyosis.\n* Female patients aged between 18 and 50.\n* Dysmenorrhea lasting for 3 consecutive menstrual cycles or more.\n* At least three consecutive menstrual cycles with an interval of 24 to 38 days, differing by less than 7 days, and menstrual periods lasting 2 to 8 days before screening.\n* At least 2 days of worst pain score ≥4 on Numerical Rating Scale during the screening period.\n* Having not used medications, other than rescue medicine, or therapies for dysmenorrhea secondary to adenomyosis for at least 1 month before randomization, and consenting not to use throughout the process of the research.\n* Volunteering to participate the trial and signing written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with Endometriosis or having a history of endometriosis-related surgery\n* Currently taking hormonal medications, including: a.use of GnRH agonists within 6 months before the screening period; b. use of progestins or danazol and other long-acting hormones within 3 months before the screening period; c. use of oral contraceptive-like short-acting hormones within one month before the screening period;\n* Having clinically significant gynecologic condition such as clinically significant endometrial pathology, persistent complex ovarian cyst larger than 3 cm or simple ovarian cyst larger than 5 cm, or single fibroid 4 cm or larger or more than 4 fibroids measuring at least 2 cm or symptomatic submucosal fibroid of any size.\n* having an IUD.\n* HB \\\u003C 90G\u002FL.\n* Having any other chronic pain syndrome that required chronic analgesic or other chronic therapy.\n* Having a current history of undiagnosed abnormal genital bleeding.\n* Malignant tumors (including the reproductive system and other systems).\n* Combined with severe diseases in the cardiac, respiratory, renal, liver, and hematopoietic systems, psychiatric disorder and\u002For cognitive disorders.\n* Pregnant, breast feeding, planning a pregnancy within the next 7 months.",{"count":219,"type":22},30,[58],"The aim of this study is to preliminarily evaluate the is to assess the effects and safety of electroacupuncture for moderate to severe dysmenorrhea secondary to adenomyosis.",[223,224,225],"Dysmenorrhea","Adenomyosis","Electroacupuncture",[223,224,225],"2025-08-01",{"date":229,"type":38},"2025-08-06",{"date":231,"type":38},"2024-07-21",{"date":233,"type":22},"2026-12-31",{"name":44,"class":45},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":167,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":255,"leadSponsor":256,"locationsCount":4},"100599021","acupuncture-for-lung-cancer-related-fatigue-100599021","NCT07079072","Acupuncture for Lung Cancer-Related Fatigue","The Effects of Acupuncture for Lung Cancer-Related Fatigue, a Clinical Trial","Inclusion Criteria:\n\n* Patients with a history of lung cancer who have completed initial treatment (including surgery, radiotherapy, and\u002For chemotherapy) at least 8 weeks prior;\n* Aged between 18 and 75 years;\n* Meet the diagnostic criteria for cancer-related fatigue;\n* Estimated to have a survival period of at least 3 months;\n* Patients with moderate to severe cancer-related fatigue (the highest fatigue score in the past 24 hours on the Chinese version of the Brief Fatigue Inventory \\[BFI-C\\] ≥ 4 points);\n* ECOG Performance Status score ranges from 0 to 2 points\n* Voluntarily join this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients experiencing significant fatigue symptoms before being diagnosed with lung cancer;\n* Patients with severe anxiety and depression;\n* Patients showing notable cognitive impairment or suicidal tendencies;\n* Patients with a history of hypothyroidism or chronic fatigue syndrome;\n* Patients suffering from moderate to severe anemia, with hemoglobin levels below 90 g\u002FL;\n* Patients experiencing severe pain, with a Numeric Rating Scale (NRS) score of 7 or higher;\n* Patients with serious sleep disorders;\n* Patients with severe malnutrition;\n* Patients with seriously diminished physical function;\n* Patients who have undergone acupuncture treatment for cancer-related fatigue within the past month;\n* Patients with uncontrolled severe underlying conditions, such as heart failure, myocardial infarction, unstable angina, endocrine disorders, gastrointestinal issues, neurological impairments, severe infections, liver and kidney failure, or chronic obstructive pulmonary disease;\n* Patients with poor adherence;\n* Patients who are breastfeeding, pregnant, or planning to conceive within the next four months.",{"count":243,"type":22},120,[58],"This study aims to evaluate the efficacy and safety of acupuncture in alleviating cancer-related fatigue (CRF) among lung cancer survivors. It addresses the key issue of limited high-quality evidence for acupuncture's effect on CRF by rigorously comparing real acupuncture against a non-penetrating sham needle control in 120 eligible participants. Patients will be centrally randomized (1:1), blinded, and receive 12-session treatment over 4 weeks. Participants will complete treatment and attend follow-up visits up to week 16, and repeatedly complete fatigue (BFI-C, MFI-20), psychological (PHQ-9, GAD-7, FCRI), functional (CWSAS), and sleep (ISI) assessments.",[247],"Lung Cancer",[249,250,201],"lung cancer","cancer-related fatigue","2025-07-22",{"date":253,"type":38},"2025-07-25",{"date":227,"type":22},{"date":233,"type":22},{"name":44,"class":45},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":167,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":280},"100587265","acupuncture-combined-with-pd-1pd-l1-inhibitors-for-advanced-lung-cancer-100587265","NCT06926140","Acupuncture Combined With PD-1\u002FPD-L1 Inhibitors for Advanced Lung Cancer","Effectiveness of Acupuncture Combined With PD-1\u002FPD-L1 Inhibitors for Advanced Lung Cancer：A Randomized Controlled Clinical Study","Inclusion criteria:\n\n* Age 18-75 years;\n* ECOG\u002FPS score of grade 0-1 and expected survival ≥ 3 months;\n* Non-small cell lung cancer AJCC lung cancer staging of stage IIIB-IV, or small cell lung cancer staging of extensive stage;\n* PD-L1 immunohistochemistry detection of tumor cell positive proportion score (TPS) \\\u003C50%;\n* Non-small cell lung cancer adenocarcinoma patients do not have EGFR-sensitive mutations, ALK fusions, ROS1 fusions, BRAFV600 mutations, NTRK fusions, RET fusions, MET14 skipping mutations, and amplified gene-driven mutations by genetic testing;\n* Patients with no previous systemic therapy\u002Ffirst-line treatment;\n* Patients suitable for chemotherapy combined with immunotherapy;\n* Traditional Chinese Medicine (TCM) diagnosis of Qi Depression;\n* Having at least 1 measurable tumor lesion (diameter \\> 1cm) or lymph node short diameter ≥ 1.5cm;\n* Sign the informed consent form and voluntarily participate in this study.\n\nExclusion criteria:\n\n* Combined with other primary malignant tumors;\n* Those who have contraindications to immunotherapy after basic assessment of immunotherapy;\n* Those with autoimmune diseases or those who need long-term treatment with systemic steroids or immunosuppressants;\n* Those with combined serious and uncontrolled primary diseases of heart, cerebrovascular, liver, kidney, hematopoietic system and so on;\n* Those with metal allergy or severe fear of needles;\n* Those who are pregnant or breastfeeding;\n* Those who are unable to cooperate to complete the assessment due to mental disorder, intellectual or language impairment;\n* Those with active severe infectious or inflammatory diseases;\n* Those who have received acupuncture treatment or other clinical trials within 1 month prior to randomization;\n* In the judgment of the investigator, persons who have a concomitant medical condition that seriously jeopardizes the safety of the participant or interferes with the completion of the study, or who are deemed to have other reasons for not being suitable for enrollment.",{"count":265,"type":22},240,[58],"This study will be an evaluation of the efficacy and safety of acupuncture to enhance the response rate of immunotherapy in advanced lung cancer. The main questions it aims to answer are 1. Does acupuncture heighten the response rate of immunotherapy in advanced lung cancer? 2. Does acupuncture heighten the safety of immunotherapy in advanced lung cancer? Researchers will compare acupuncture to sham acupuncture to see if acupuncture could enhance the response rate of immunotherapy in advanced lung cancer. Both groups will receive a standard anti-tumor Western medical treatment regimen (PD-1\u002FPD-L1 inhibitor combined with chemotherapy), and the experimental and control groups will be treated with 4 cycles of acupuncture or sham-acupuncture on top of the anti-tumor treatment regimen, respectively. Patients were followed up every three weeks for the first three months and every three months thereafter to record any disease progression, adverse events, survival or mortality status, and so on.",[269],"Lung Cancers",[249,201,271],"immunotherapy","2025-07-21",{"date":274,"type":38},"2025-07-24",{"date":276,"type":38},"2025-06-21",{"date":278,"type":22},"2028-07-31",{"name":44,"class":45},3,{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":167,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":46},"100394372","taes-for-fpvcs-a-pragmatic-randomized-controlled-trial-100394372","NCT04415203","TAES for FPVCs: a Pragmatic, Randomized Controlled Trial","Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Frequent Premature Ventricular Complexes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed as frequent premature ventricular contractions;\n* 2 ≤ Lown level ≤ 4A;\n* 18 ≤ age ≤ 75;\n* Volunteered to participant\n\nExclusion Criteria:\n\n* Severe valvular disease, congenital heart disease, pericardial disease, hypertrophic cardiomyopathy, unstable angina pectoris, acute myocardial infarction, myocarditis, aneurysm, congestive heart failure decompensation period (NYHA grade III or VI), cardiogenic shock, cerebrovascular disease, hematopoietic system disease, severe mental disease;\n* Bradycardia, including pathologic sinus node syndrome, degree II or greater atrioventricular block;\n* Those who have already had pacemaker or percutaneous coronary intervention, or who plan to have pacemaker or percutaneous coronary intervention;\n* Pregnant or lactating women;\n* Local sensory deficit, or allergic to current;\n* May be allergic to percutaneous patches；\n* Blood pressure ≤ 90\u002F60 mmHg;\n* Those who have participated in other clinical trials within 3 months.",{"count":289,"type":22},90,[58],"This prospective, randomized controlled trial aims to evaluate the efficacy and safety of Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS) for patients with frequent premature ventricular coomplexes (FPVCs). Ninety participants will be randomized to TAVNS group and sham-TAVNS group with the ratio of 1:1. They will receive TAVNS plus usual care or sham-TAVNS plus usual care for 6 weeks, and then be followed up for 12 weeks after the treatment. The primary outcome was the proportion of participants with a 50% decrease of the 24 hour (24h) premature ventricular complexes (PVCs) after 6-week treatment. Secondary outcomes include the proportion of participants with a 75% decrease of the 24h-PVCs; the decrease from baseline of 24h-PVCs, total 24h-heartbeat, and the frequency of supraventricular arrhythmia; the score change from baseline in PVCs-related symptoms; the score change from baseline in SAS and SDS. Subgroup analyses will be performed in age, gender, and the severity of PVCs. Safety assessment will be documented during the whole trial.",[293],"Premature Ventricular Complexes","2025-07-16",{"date":296,"type":38},"2025-07-20",{"date":298,"type":38},"2020-06-04",{"date":300,"type":22},"2025-12",{"name":44,"class":45},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":143,"sex":18,"minAge":19,"maxAge":54,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":46},"100577759","efficacy-and-central-mechanisms-of-electroacupuncture-for-medication-overuse-headache-100577759","NCT06802471","Efficacy and Central Mechanisms of Electroacupuncture for Medication Overuse Headache","Efficacy and Central Mechanism of Electroacupuncture for Medication Overuse Headache: a Multicenter Randomized Controlled Trial","Inclusion Criteria for Patients with MOH:\n\n* Meet the diagnostic criteria of MOH in ICHD-3;\n* A history of migraine (according to ICHD-3 criteria)\u002Ftension headache (TTH) (according to ICHD-3 criteria) for ≥12 months before screening;\n* Patients entered data from the electronic headache diary for at least 24 of the 28 days of the screening period (evidence of good adherence to the electronic headache diary);\n* Prospectively collected data from the electronic headache diary during the screening period met the following criteria: 15 or more headache days per month; Regular overdose of acute or symptomatic headache medications meets the diagnostic criteria for MOH；\n* Headache diagnosed before the age of 50 years;\n* Patients had failed MOH withdrawal treatment (with medical documentation or specific physician confirmation of each treatment) on ≥1 occasions in the previous 3 years; Withdrawal treatment failure is defined as no significant reduction in headache frequency, duration and\u002For severity after withdrawal treatment; Or intolerable withdrawal reactions during withdrawal treatment; Or unable to quit treatment due to safety issues;\n* Aged between 18 and 80 years old;\n* Signed the informed consent and volunteered to participate in the study.\n* Patients who met the above 8 criteria were included in this study.\n\nExclusion Criteria for Patients with MOH:\n\n* Patients had a history or diagnosis of hypotensive headache, continuous hemiplegia, new daily persistent headache, or unusual migraine subtypes, such as hemiplegic migraine (sporadic and familial), ocular tension migraine, migraine with neurologic symptoms that were atypical of migraine aura (diplopia, altered consciousness, or prolonged duration). Other types of primary or secondary headache;\n* The presence of clinically significant pain syndromes that may be confusing (e.g., fibromyalgia, chronic low back pain, complex regional pain syndrome); Acute or active temporomandibular joint disorders;\n* The patient had an uncontrolled and\u002For untreated mental illness (e.g., severe depression and schizophrenia) for at least 6 months prior to the screening visit; Patients with a history of psychosis and\u002For mania within 5 years before screening were excluded;\n* The patient has any other medical condition whose treatment takes precedence over MOH treatment or may interfere with the study treatment or impair compliance with treatment;\n* Taking\u002Fusing medications\u002Fstimulation devices that may affect headache (e.g., beta-blockers (atenolol, propranolol, metoprolol, etc.) due to headache or other reasons within 3 months before or during the screening period; Calcium channel blockers (flunarizine, benzothiazide, etc.); Antidepressants (amitriptyline, venlafaxine, duloxetine, etc.); Antiepileptic drugs (topiramate, sodium valproate, carbamazepine, etc); Angiotensin-receptor blockers (candesartan and lisinopril); Botulinum toxin; Gabapentin; Noninvasive vagus nerve stimulation, transcranial magnetic stimulation, peripheral trigeminal nerve stimulation; Biofeedback, health products; Occipital nerve block, other nerve block; Continuous infusion therapy, steroid reduction; Chiropractic therapy, physical therapy); Or treatment with injections (trigger point injections, extracranial nerve blocks or facet joint injections) on the head, face or neck;\n* The patient has a history of moderate or severe head or neck trauma, or other neurological or systemic diseases (such as epilepsy and dementia) that the researcher believes may affect the central nervous system function;\n* Patients have or have had one or more of the following conditions that were considered in the study to be associated with clinical symptoms: other neurological, pulmonary, hepatic, endocrine, gastrointestinal, hematologic, infectious, immunologic, or ocular conditions;\n* A history of substance or alcohol abuse (according to DSM-5® criteria) within 24 months prior to the screening visit;\n* During the screening or baseline visit, the patient has significant suicide risk (answers \"Yes\" to question 4 or 5 on the C-SSRS suicide ideation section, or answers \"Yes\" to any question regarding suicidal behavior at any time during the study on the C-SSRS);\n* Prophylactic treatment for headache was received 1 month before the screening visit;\n* One month before the screening visit, the patient had participated in a clinical study; Or had taken any medication for headache within the 5 plasma half-lives, whichever was longer, before the screening visit;\n* Severe uncontrolled disease such as cancer, uncontrolled cardiovascular disease, severe hepatic and renal insufficiency, or coagulopathy; Women who are pregnant or preparing to become pregnant;\n* Having known fear of acupuncture or having received acupuncture treatment within 8 weeks before enrollment;\n* In the judgment of the investigators, the patients have diseases or take drugs that may affect the assessment of the safety, tolerability, or efficacy of the trial, or affect the conduct or interpretation of the study.\n* Any one of the above items is excluded.\n\nInclusion Criteria for Patients with episodic migraine(Control group 1):\n\n* According to the ICHD-3 criteria, it met the diagnostic criteria of episodic migraine; With\u002Fwithout tension-type headache;\n* Headache days\u002Fmonth ≤6 days at enrollment;\n* The number of days\u002Fmonth of using analgesics at enrollment was ≤6 days;\n* Age between 18 and 80 years;\n* Be able to fill out a headache diary;\n* No previous history of drug abuse;\n* No obvious comorbidities pain, physical or mental disorders;\n* No alcohol or drug addiction;\n* No pregnancy, breastfeeding, or plans for pregnancy in the next 12 months;\n\nInclusion Criteria for Healthy Participants(Control group 2):\n\n* No headache or headache ≤2 days in the past 12 months at enrollment;\n* No more than 6 days\u002Fmonth of use of analgesics at enrollment;\n* Age between 18 and 80 years;\n* No significant comorbidities pain, physical, or mental disorders;\n* No organic, functional changes or systemic diseases that could cause headache;\n* No history of head or neck trauma;\n* No significant abnormalities in blood routine, biochemical tests, coagulation function, or urine routine in the past 12 months prior to enrollment;\n* No alcohol or drug addiction;\n* No pregnancy, breastfeeding, or plans for pregnancy in the next 12 months.\n\nNonrandomized patients with MOH:\n\n●Participants who meet the MOH diagnostic criteria and fulfill the inclusion\u002Fexclusion criteria but decline randomization will be assigned to the non-randomized electroacupuncture group. These participants will receive electroacupuncture treatment directly, with no restrictions on the number of participants per center.",{"count":310,"type":22},160,[58],"Acupuncture is commonly used for the prevention of migraine and tension-type headaches, and has been found to be effective in reducing both the frequency and severity of these conditions. However, studies on acupuncture for medication overuse headache (MOH) are limited, and current research has not been able to determine whether its efficacy is due to the actual therapeutic effects of acupuncture or psychological benefits. To address this issue, the investigators have designed a clinical trial to evaluate the efficacy of acupuncture for MOH. In addition, the investigators will explore the regulatory effects of electroacupuncture on central mechanisms in MOH and conduct multi-omics analysis.",[314,225],"Medication Overuse Headache","2025-07-13",{"date":294,"type":38},{"date":318,"type":38},"2025-02-01",{"date":320,"type":22},"2027-06",{"name":44,"class":45},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":167,"enrollmentInfo":328,"targetDuration":4,"studyType":23,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":338,"locationsCount":46},"100537989","acupuncture-of-different-treatment-frequency-in-chronic-plantar-fasciitis-100537989","NCT06284993","Acupuncture of Different Treatment Frequency in Chronic Plantar Fasciitis","Inclusion Criteria:\n\n* Patients with a diagnosis of chronic PF with a disease course of ≥ 6 months;\n* The most painful heel pain in the morning is Visual Analogue Scale (VAS; 0 indicating no pain and 100 indicating maximal pain) ≥ 40 mm on a 100 mm VAS;\n* Patients between the ages of 18 and 75 years;\n* Patients should be conscious, free from mental disorders, and without serious heart, liver, or kidney diseases; and\n* Willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* History of calcaneal tuberosity fracture\u002Fcalcaneal stress fracture\u002Fcalcaneal contusion\u002Fplantar fascia rupture;\n* History of ankle or foot surgery;\n* Achilles tendon enthesis lesion\u002Ftarsal tunnel syndrome\u002Fmedial calcaneal nerve entrapment\u002Fnerve injury;\n* Systemic or local infection, severe cracked heel, foot deformity (e.g., high arched feet, flat feet, foot valgus);\n* Systemic diseases (e.g., obligatory spondylitis, rheumatoid arthritis, seronegative arthritis, autoimmune system diseases, tumors, diabetes ) and other situations judged by the investigators not to be suitable for the clinical trial;\n* Pregnant women; patients with severe combined cardiac, hepatic, renal, hematopoietic, and patients with cardiac pacemakers , and patients with severe poor general nutritional status;\n* Cognitive impairment, inability to understand the content of the scale evaluation;\n* Topical steroid injection or oral use in the past 6 months;\n* Patients with a known fear of acupuncture or who have been treated with acupuncture in the past 8 weeks.",{"count":329,"type":22},80,[58],"Plantar fasciitis (PF) is one of the most common causes of heel pain, typically characterized by a sharp pain in the plantar aponeurosis, specifically near the insertion site close to the medial process of the calcaneal tuberosity. It has been reported that 1 in 10 people are expected to be affected by PF in their lifetime. A comprehensive internet-panel survey conducted among the adult United States population revealed the population-based prevalence of self-reported PF with pain in the last month was 0.85 percent. Approximately 1 million patients are diagnosed with this disease each year in the United States. PF was believed to be an acute inflammatory disease, but patient samples show it is actually a chronic degenerative process caused by various factors such as repetitive stresses, vascular and metabolic disorders, excess free radicals, high temperatures, genetic factors, and conditions like rheumatoid arthritis and spondyloarthropathies. PF may be associated with impaired health-related quality of life, including reduced life functioning, poor perceived health status and social isolation. Additionally, a recent study indicates that the annual cost associated with PF is $284 million.\n\nThe first-line treatments recommended by guidelines for PF encompass physical therapy (including manual therapy, stretching, and others), pharmacological therapy (involving corticosteroids or platelet-rich plasma), and surgical treatment. However, the definite effects of physical therapy still require confirmation. Pharmacological treatments, such as local corticosteroid injections, exhibit a short maintenance period. Some studies indicate that the relief provided by corticosteroid injections lasts up to one month, yet its efficacy diminishes after 6 months. Surgical treatment is generally advised 6 to 12 months after unsuccessful conservative treatment, albeit with the drawback of higher costs, post-surgery recovery time, and patient apprehension.\n\nAcupuncture is one of the most common complementary alternative therapy for the treatment of pain-related diseases such as musculoskeletal muscle, and recent guidelines recommend dry needling as a treatment for relief of plantar fasciitis, with a level of evidence of B. Dry acupuncture is different from acupuncture in terms of theoretical basis, therapeutic apparatus, technical operation and scope of indications, however, the American Alliance for Professional Acupuncture Safety also believes that dry needling falls under the umbrella of acupuncture, but under a different name. In addition, there are systematic evaluations that suggest acupuncture can be a safe and effective treatment for PF, and most of the trials in the systematic evaluations used 4-week treatment courses. Our prior study demonstrated that a 4-week intervention of both electroacupuncture and manual acupuncture resulted in improved pain outcomes among patients with PF.\n\nThe frequency of acupuncture stands as a crucial factor influencing its efficacy. A study revealed that needling trials with negative results had a significantly lower frequency compared to those yielding positive results. Furthermore, several studies indicate that acupuncture once a week can be help in conditions such as simple obesity, functional dyspepsia, and overactive bladder in women. There is no universally accepted standard of frequency of treatment for many conditions, including PF. In China, patients with chronic diseases usually receive 3-5 acupuncture treatments per week. However, in most previous trials, individuals with chronic diseases received 1-2 needling sessions per week. An increase in the frequency of acupuncture means an increase in the pain, time, and financial investment associated with the acupuncture process. Therefore, it is critical to optimize the frequency of acupuncture to ensure the effectiveness and feasibility of the treatment while avoiding increasing the burden on the patient. Accordingly, the investigators designed the current trial to compare the effects of different acupuncture sessions (1 session per week versus 3 sessions per week) in a randomized controlled trial (RCT) of chronic PF. The hypothesis is that 1 session per week compared with 3 sessions per week of electroacupuncture treatment over a total of 4 weeks of treatment will provide a similar effect on pain relief in chronic PF.",[333],"Plantar Fasciitis, Chronic",{"date":294,"type":38},{"date":336,"type":38},"2024-05-21",{"date":159,"type":22},{"name":44,"class":45},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":54,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":46},"100459782","acupuncture-vs-sham-acupuncture-for-hand-osteoarthritis-100459782","NCT05267093","Acupuncture vs Sham Acupuncture for Hand Osteoarthritis","Efficacy of Acupuncture for Patients With Hand Osteoarthritis: a Randomized, Sham-controlled Trial","Inclusion Criteria:\n\n* Diagnosed as hand OA according to the American College of Rheumatology (ACR) clinical classification criteria\n* History of hand OA for at least 3 months before enrollment and history of taking nonsteroidal anti-inflammatory drugs (NSAIDs) to treat hand OA\n* Aged 18-80 years\n* At least 40 mm in visual analog scale (VAS) on the average pain intensity of the dominant hand over the last 48 hours (patients applying NSAIDs at the screening have to have an increase in pain in the dominant hand of ≥ 20 mm after 1-week washout)\n* Posterior-anterior radiographs of the dominant hand shows Kellgren-Lawrence grade 1, 2, or 3 changes in symptomatic joints\n* Negative results in both rheumatoid factor and anticyclonic citrullinated peptide\n* Able to comply with the study protocol and understand the medical information forms\n* Voluntarily sign the informed consent\n\nExclusion Criteria:\n\n* History or current evidence of secondary OA (due to causes other than a solely degenerative joint disease) or symptomatic OA at additional locations besides the hand(s) requiring treatment, or any painful syndrome of the upper limb which may interfere with evaluation of hand pain;\n* History of inflammatory arthritis (such as rheumatoid arthritis (RA) or psoriatic arthritis), hemochromatosis, metabolic, or neuropathic arthropathies;\n* History of trauma, dislocation or operation to the hand or arm in the previous 3 months;\n* Hand pain and stiffness due to tissue scarring or tendinitis;\n* Skin damage or serious skin disorders in the hands;\n* Intake of antidepressants, anticonvulsants, vascular or narcotics during the 10 days prior to beginning the study;\n* Oral, intramuscular, intra-articular or intravenous corticosteroids, or hyaluronic acid injection within 3 months preceding enrollment;\n* Serious uncontrolled medical conditions such as cancer, uncontrolled cardiovascular disorder, severe hepatic\u002Frenal insufficiency or coagulation disorder;\n* Known phobic to acupuncture or received acupuncture treatment within 4 weeks prior to enrollment.",{"count":347,"type":22},340,[58],"The investigators plan to conduct this multicentered, sham-controlled randomized clinical trial to evaluate the efficacy and safety of acupuncture for clinical symptomatic improvement of hand OA.",[351],"Hand Osteoarthritis",{"date":294,"type":38},{"date":354,"type":38},"2022-04-26",{"date":356,"type":22},"2026-12",{"name":44,"class":45},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":167,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":374,"locationsCount":46},"100425112","acupuncture-at-the-sphenopalatine-ganglion-in-the-treatment-of-moderate-to-severe-seasonal-allergic-rhinitis-100425112","NCT04815668","Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis","Effect of Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis","Inclusion Criteria:\n\n1. Age ≥18 years and ≤ 75 years;\n2. History of moderate to severe SAR symptoms (Visual analog scale(VAS) \\>50 mm, range, 0 cm\\[not at all bothersome\\] to 100 mm\\[extremely bothersome\\]) for more than 4 days\u002Fweeks, and more than 4 consecutive weeks with at least two years' duration;\n3. Positive skin prick test to grass and birch pollen or\u002Fand serum-specific IgE test;\n4. Ability to complete the medical information form and sign a written informed consent.\n\nExclusion Criteria:\n\n1. History or current evidence of perennial allergic rhinitis, acute sinusitis, allergic asthma, pneumonia; autoimmune disorders, or severe chronic inflammatory diseases;\n2. History of nasal rhinopolypus or abnormalities;\n3. Intake of antihistamines, anticholinergics, corticosteroids, decongestants, or antibiotics during the 1 month prior to beginning the study;\n4. History of systemically administered corticosteroids within 6 months or specific immunotherapy, allergy desensitization therapy within 1 year before enrollment;\n5. Serious uncontrolled blood coagulation disorder, cardiovascular disorder, severe hepatic\u002Frenal insufficiency or mental disorder;\n6. Pregnancy or planning for pregnancy;\n7. Known allergy, or contraindication to rescue medication or related drugs;\n8. Known phobia to acupuncture or having received acupuncture treatment, or sphenopalatine ganglion stimulation or other complementary and alternative medicine within 1 months prior to enrollment.",{"count":243,"type":22},[58],"Allergic rhinitis (AR) is an immunoglobulin E-mediated inflammatory disease1 caused by hypersensitivity of the immune system to an allergen, affecting 100 million people in Europe 2and 400 million of the global population.The etiology of AR is multifactorial, resulting primarily from genetic predisposition, immunological response, and environmental pollutants.AR traditionally has been classified as seasonal (SAR) or perennial (PAR) depending on the causes and duration of symptoms. Some patients with AR prefer complementary and alternative medicine for their symptoms, with nearly 20% receiving acupuncture. According to the updated practice parameter of rhinitis in 2020, the use of acupuncture for the treatment of AR was not recommended due to a lack of well-controlled studies.\n\nThe sphenopalatine ganglion (SPG), located under a thin (1-2 mm) layer of mucosa in the pterygopalatine fossa, consists of sensory fibers that innervate the nasopharynx, nasal cavity, and palate.Several studies have reported the benefit of SPG stimulation in chronic cluster headache and acute ischaemic stroke. Compared with traditional acupoints selected on basis of traditional meridian theory, acupuncture at SPG(inserting a needle through SPG acupoint (near ST7, Xiaguan) to reach and directly stimulate the SPG) may help patients ameliorate nasal symptoms immediately and improve quality of life by increasing sympathetic nerve excitability, but the evidence is inconclusive.\n\nWe have designed this three-armed, randomized trial to investigate the efficacy and safety of acupuncture at SPG for the treatment of SAR. We hypothesize that acupuncture at SPG plus rescue medication is superior to sham acupuncture plus RM and RM alone in the treatment of SAR.",[369],"Seasonal Allergic Rhinitis",{"date":294,"type":38},{"date":372,"type":38},"2021-05-01",{"date":233,"type":22},{"name":44,"class":45},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":167,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":393,"leadSponsor":395,"locationsCount":4},"100592652","effect-of-acupuncture-on-chronic-nonspecific-neck-pain-and-insomnia-100592652","NCT06996210","Effect of Acupuncture on Chronic Nonspecific Neck Pain and Insomnia","Efficacy of Acupuncture in Treating Comorbid Chronic Nonspecific Neck Pain and Insomnia","Inclusion Criteria:\n\n1. Aged 18 to 75 years old;\n2. Meet the diagnostic criteria for both chronic nonspecific neck pain and chronic insomnia;\n3. The patient's average 24-hour overall neck pain intensity score on the NRS is ≥3;\n4. The patient's Insomnia Severity Index (ISI) score is ≥10;\n5. The patient is willing to participate in the study and has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Specific neck pain with a clear etiology, including trauma, tumor, connective tissue disease, rheumatic disease, metabolic and endocrine disorders, neuropathy, spinal cord disease, fracture, or vertebral misalignment;\n2. Positive Spurling test, neck flexion test, upper limb traction test, or foraminal distraction test. Neck pain accompanied by radiating pain in the upper limbs or radicular compression symptoms, or acute exacerbation of neck pain;\n3. Neck pain accompanied by sensory disturbances or other neurological symptoms, or ankylosis of the facet joints;\n4. Previous history of cervical spine surgery;\n5. Previous history of head and neck trauma, such as whiplash injury;\n6. Insomnia caused by medications (e.g., caffeine, corticosteroids), withdrawal reactions, or other underlying conditions (e.g., hyperthyroidism, severe anxiety\u002Fdepressive disorders);\n7. Long-term use of analgesics, muscle relaxants, or hormones, or presence of other pain more severe than neck pain;\n8. Other sleep disorders, such as sleep apnea syndrome, or shift workers;\n9. Presence of psychiatric disorders (e.g., depression), cognitive impairment, or language disorders;\n10. Patients with drug dependency;\n11. Received acupuncture treatment within the past month;\n12. Severe cardiovascular, hepatic, renal, hematologic, autoimmune diseases, infectious diseases, poor general nutritional status, malignancy, or patients in the terminal stage of severe illness;\n13. Pregnant or planning to become pregnant within the next year, breastfeeding, or postpartum ≤12 months.",{"count":383,"type":22},124,[58],"The study aims to assess the efficacy and safety of acupuncture among patients with chronic nonspecific neck pain and insomnia, compared with sham acupuncture.",[387,388],"Neck Pain Chronic","Insomnia Chronic","2025-07-10",{"date":391,"type":38},"2025-07-15",{"date":67,"type":22},{"date":394,"type":22},"2028-03-27",{"name":44,"class":45},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":144,"minAge":19,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":23,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":46},"100594782","the-efficacy-and-safety-of-acupuncture-for-prophylaxis-of-menstrually-related-migraine-100594782","NCT07023926","The Efficacy and Safety of Acupuncture for Prophylaxis of Menstrually Related Migraine","The Efficacy and Safety of Acupuncture for Prophylaxis of Menstrually Related Migraine: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. meet the diagnostic criteria for MRM according to the ICHD-3, with a documented history of MRM for at least 12 months;\n2. have a confirmed diagnosis of migraine by a neurologist;\n3. aged 18-45 years;\n4. have regular menstrual cycles (28 ± 7 days) with menstruation lasting 3-7 days;\n5. have experienced ≥3 headache days during each menstrual cycle (days -2 to +3) and ≥5 total headache days per cycle over the past 3 months and baseline period; migraine attacks must last 4-72 hours without acute medication, or at least 2 hours when treated;\n6. have completed a headache diary during the screening period (covering at least one full menstrual cycle), demonstrating good compliance;\n7. headache diary data during screening period must meet the ICHD-3 criteria for MRM and fulfill criteria (4) and (5);\n8. voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n1. irregular menstrual cycles, defined as cycle length outside the range of 28±7 days or menstruation duration \\\u003C3 days or \\>7 days;\n2. presence of secondary headache disorders, facial neuralgia, or cranial neuralgia;\n3. combined with serious primary diseases such as cardiovascular, hepatic, renal, gastrointestinal, or hematological disorders that may interfere with the treatment protocol, or comorbid neurological conditions such as epilepsy, parkinson's disease, or other central nervous system disorders;\n4. headache symptoms caused by other conditions, such as moderate to severe head or neck trauma, perimenstrual infections, intracranial tumors, intracranial infections, endocrine or metabolic disorders;\n5. receipt of preventive treatment for headache within 1 month prior to the screening visit;\n6. afraid of needles or received acupuncture treatment within 3 months;\n7. unwillingness to undergo the study intervention or failure to sign the informed consent.","45 Years",{"count":405,"type":22},40,[58],"Acupuncture is commonly used for the prevention of migraine and tension-type headaches, and has been found to be effective in reducing both the frequency and severity of these conditions. However, studies on acupuncture for menstrually related migraine (MRM) are limited, and current research has not been able to determine whether its efficacy is due to the actual therapeutic effects of acupuncture or psychological benefits. To address this issue, the investigators have designed a clinical trial to evaluate the efficacy of acupuncture for MRM.",[409,225],"Menstrually Related Migraine","2025-06-14",{"date":412,"type":38},"2025-06-17",{"date":414,"type":22},"2025-07-01",{"date":416,"type":22},"2027-01-31",{"name":44,"class":45},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":144,"minAge":19,"maxAge":145,"enrollmentInfo":425,"targetDuration":4,"studyType":23,"phases":427,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":46},"100592509","acupuncture-for-anxiety-and-depression-100592509","NCT06994351","Acupuncture for Anxiety and Depression","The Effects of Acupuncture on Anxiety and Depression of Patients With Breast Cancer","Inclusion criteria\n\n1. Female, aged 18 to 70 years old;\n2. Meeting the diagnostic criteria for breast cancer and at TMN I-III;\n3. Having completed specialized active treatment for at least one month;\n4. With an ECOG score of 0-2;\n5. Mild to moderate anxiety and\u002For depression;\n6. Voluntarily joining this study and signing the informed consent form. Exclusion criteria\n\n(1) Starting to take or change the regimen of anti-anxiety and\u002For -depression disorder medication within one month before enrolment; (2) Received psychological intervention or physical therapy one month before enrolment or planning to use in the next 5 months; (3) With diagnosis of anxiety and\u002For depression disorder prior to the diagnosis of breast cancer; (4) Patients with suicidal tendencies, bipolar disorder and psychotic symptoms; (5) Patients with severe anxiety and\u002For depression； (6) Patients received acupuncture treatment within one month before enrolment; (7) Participating in other clinical studies on the treatment of anxiety and depression; (8) Combined with severe underlying diseases; (9) Patients with severe skin ulcers; (10) Pregnant or lactating patients; (11) Poor compliance.",{"count":426,"type":22},20,[58],"The study aims to primarily investigate the effects and safety of acupuncture on anxiety and depression among patients with breast cancer.",[430,431],"Anxiety and Depression","Breast Cancer Survivor","2025-05-25",{"date":434,"type":38},"2025-05-29",{"date":436,"type":22},"2025-05-18",{"date":438,"type":22},"2025-12-31",{"name":44,"class":45},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":449,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":463,"locationsCount":46},"100507999","phase-4-survival-benefit-of-compound-kushen-injection-in-the-treatment-of-advanced-colorectal-cancer-100507999","NCT05894694","Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer","Survival Benefit of Compound Kushen Injection in Treatment of Advanced Colorectal Cancer Based on Real World Registration Platform","Inclusion Criteria:\n\n① Patients with advanced CRC confirmed by pathology or cytology and receiving first-line therapy;② Aged ≥ 18 years old, male or female;③ ECOG score 0-2 points;④ Expected survival ≥ 3 months;⑤ According to RECIST1.1 criteria, at least one detectable lesion;⑥ Voluntarily join the study, sign informed consent, compliance with good cooperation with follow-up.\n\nExclusion Criteria:\n\n* Combined with other malignant primary tumors;\n\n  * Immunohistochemistry\u002Fpolymerase chain reaction\u002Fsecond-generation sequencing results suggest MSI-H\u002FdMMR patients;\n\n    * Patients with recurrence and metastasis within 6 months after radical tumor surgery;\n\n      * Patients who have previously or are undergoing cancer immunotherapy ; Patients undergoing radiation therapy;\n\n        * Pregnant or lactating women; women of childbearing age and their spouses can not take effective contraceptive measures during and within 6 months after the end of clinical study; ⑥ Psychiatric patients; ⑦ Patients with severe, uncontrolled organic disease or infection, such as decompensated heart, lung, kidney failure caused by intolerance to chemotherapy; ⑧ Patients who have received clinical trials of small molecule drugs within 28 days or received clinical trials of large molecule drugs within 3 months; ⑨ Patients who are known to be allergic to or intolerant of study drugs.",{"count":448,"type":22},320,[450],"PHASE4","To clarify the effectiveness and safety of compound kushen injection in the treatment of advanced colorectal cancer.",[453],"Advanced Colorectal Carcinoma",[455,456],"Compound kushen Injection","Traditional Chinese medicine","2024-12-21",{"date":459,"type":38},"2024-12-27",{"date":461,"type":38},"2023-09-27",{"date":438,"type":22},{"name":44,"class":45},{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":18,"minAge":471,"maxAge":54,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":478,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":46},"100554988","effects-of-acupuncture-for-senile-pruritus-100554988","NCT06506240","Effects of Acupuncture for Senile Pruritus","Effects of Acupuncture for Senile Pruritus: Study Protocol for a Randomised Controlled Trial","Inclusion Criteria:\n\nParticipants aged between 60 and 80 years who meet diagnostic criteria for SP, with an average severity score of itching in the past week of ≥4 points on the Numerical Rating Scale (NRS), and who voluntarily provide written informed consent are eligible for inclusion.\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Severe skin damage or infection;\n2. Severe underlying diseases including cardiovascular diseases, hepatobiliary diseases, kidney diseases, hematologic diseases, autoimmune diseases, infectious diseases, severe malnutrition, or malignancies;\n3. Mental illness, cognitive dysfunction, or language disorders;\n4. Received acupuncture therapy for pruritus within the past month;\n5. Have a history of drug abuse.","60 Years",{"count":473,"type":22},108,[58],"Senile pruritus (SP), characterized by idiopathic itching in individuals aged 60 years and older without primary skin lesions, significantly impacts sleep and quality of life. Effective alternative treatments are needed. Acupuncture has been suggested as a potential intervention to alleviate itching; however, its role in managing SP remains uncertain. This study aims to evaluate the effects and safety of acupuncture for SP. This single-centre, parallel, two-arm, randomized, sham-controlled trial will enroll 108 patients diagnosed with SP in a 1:1 ratio to either the acupuncture or sham acupuncture group. Participants, outcome assessors, and the statistician will be blinded. Treatment will consist of 18 sessions over 6 weeks. The primary outcome is change from baseline in the Numerical Rating Scale (NRS) score for average itching severity at week 6, assessed weekly via weekly diary of pruritus assessment. Secondary outcomes include changes in NRS score for maximum itching severity, daily episodes of itching, itchy area of body surface, overall dry skin score (ODS), the Dermatology Life Quality Index (DLQI), the Pittsburgh Sleep Quality Index (PSQI), the Hospital Anxiety and Depression Scale (HADS), and Patient Global Impression of Change (PGIC). Adverse events will be monitored throughout the study period. The intention-to-treat (ITT) population will include participants who complete baseline assessments and receive at least one treatment session.",[477],"Senile Pruritus",[87,479,480],"Senile pruritus","Randomized controlled trial","2024-11-18",{"date":483,"type":38},"2024-11-20",{"date":485,"type":38},"2024-03-01",{"date":487,"type":22},"2026-02-28",{"name":44,"class":45},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":496,"maxAge":167,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":499,"briefSummary":500,"conditions":501,"keywords":503,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":4},"100567943","phase-4-efficacy-and-safety-of-tongren-dahuoluo-bolus-in-patients-with-knee-osteoarthritis-100567943","NCT06674759","Efficacy and Safety of Tongren-Dahuoluo Bolus in Patients with Knee Osteoarthritis","Efficacy and Safety of Tongren-Dahuoluo Bolus in Patients with Knee Osteoarthritis: a Randomized, Double-blind, Placebo-controlled Clinical Study","Inclusion Criteria:\n\n1. Male or female, aged 40 to 75 years old;\n2. Meet the diagnostic criteria for primary knee osteoarthritis (KOA) (the diagnostic criteria refer to the 1995 American College of Rheumatology classification criteria for knee osteoarthritis);\n3. Meet the diagnostic criteria for liver and kidney deficiency and (or) cold and dampness obstruction in the group standard of the Chinese Association of Traditional Chinese Medicine \"Guidelines for Combination of Osteoarthritis Symptoms\";\n4. X-ray examination of the joints is graded as I to III (knee joint Kellgren\u002FLawrence e scoring standard);\n5. Knee pain score ≥40mm in the past week (assessed by VAS standard);\n\nExclusion Criteria:\n\n1. Patients with other rheumatic diseases such as Sjögren's syndrome, gout, rheumatoid arthritis, or a history of human immunodeficiency virus (HIV);\n2. Patients with severe lesions of important organs such as the heart, liver, and kidney, abnormal liver function (alanine or aspartate aminotransferase or glutamine transpeptidase\\>1.5 times the upper limit of normal value); or abnormal renal function (serum creatinine level\\> upper limit of normal value); white blood cell (white blood cell, WBC) or platelet (platelet, PLT) below the lower limit of normal value; or diabetic patients with poor blood sugar control in the recent period (glycosylated hemoglobin\\>8.0%);\n3. Patients with suppurative, nonspecific, and other infectious knee arthritis;\n4. Patients with traumatic, villonodular pigmentation and other lesions with knee synovium as the main lesions;\n5. Patients with advanced joint deformity or disability; A randomized controlled study on Tongren Dahuoluowan in the treatment of knee osteoarthritis Version number: 2023009P8A01 Version date: December 23, 2022\n6. Allergic constitution and allergic to the test drug;\n7. Pregnant, pregnant, or lactating women;\n8. Those who are taking antidepressants, anticonvulsants, opioids, sedatives and glucocorticoids;\n9. Patients who have received intra-articular treatment with sodium hyaluronate within 4 weeks before screening; those who have taken drugs containing chondroitin sulfate\u002Fglucosamine\u002Fdiacerein within 3 months before screening; those who have used biological agents within 3 months before screening;\n10. Patients with organ failure symptoms;\n11. Those who have participated in any other drug trials within 1 month before selection;\n12. Those who the researcher believes are not eligible to join this clinical trial","40 Years",{"count":498,"type":22},72,[450],"The clinical trial has a research cycle of 24 weeks. The first 12 weeks are multicenter, randomized, double-blind, controlled trials. A total of 72 patients with knee osteoarthritis with liver-kidney deficiency syndrome and\u002For cold-dampness arthralgia syndrome are planned to be enrolled and randomly assigned to the control group (Tongren-Dahuoluo Bolus) and the treatment group (Tongren-Dahuoluo Bolus Placebo) in a 1:1 ratio. The purpose is to compare the safety and efficacy of Tongren-Dahuoluo Bolus and placebo in treating knee osteoarthritis. A long-term blind extension study will be conducted in the next 12 weeks. All subjects will take Tongren-Dahuoluo Bolus orally to evaluate the long-term safety, tolerability, and efficacy of Tongren-Dahuoluo Pills in treating patients with knee osteoarthritis.",[502],"Knee Osteoarthritis (Knee OA)",[504,505],"Tongren-Dahuoluo Bolus","Knee osteoarthritis (Knee OA)","2024-11-03",{"date":508,"type":38},"2024-11-05",{"date":510,"type":22},"2025-01-10",{"date":512,"type":22},"2025-12-30",{"name":44,"class":45},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":529,"leadSponsor":531,"locationsCount":46},"100557076","using-the-chinese-indigenization-fs-scale-in-the-diagnosis-of-fibromyalgia-specificity-and-sensitivity-in-clinical-practice-100557076","NCT06533410","Using the Chinese Indigenization FS Scale in the Diagnosis of Fibromyalgia： Specificity and Sensitivity in Clinical Practice","Inclusion Criteria:\n\n* At least 18 years of age; Patients with chronic widespread pain; Able to complete the questionnaire.\n\nExclusion Criteria:\n\n* Terminal patients with severe psychiatric diseases, tumors, systemic lupus erythematosus, systemic sclerosis, or other serious diseases.",{"count":521,"type":22},59,"This study aimed to evaluate the specificity and sensitivity of the diagnostic criteria for fibromyalgia after conducting local validation in China.",[524],"Fibromyalgia","2024-10-17",{"date":527,"type":38},"2024-10-21",{"date":336,"type":38},{"date":530,"type":22},"2025-05-31",{"name":44,"class":45},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":145,"enrollmentInfo":539,"targetDuration":4,"studyType":23,"phases":541,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":4},"100563407","acupuncture-for-symptom-relief-in-adults-with-mild-to-moderate-ulcerative-colitis-100563407","NCT06615765","Acupuncture for Symptom Relief in Adults with Mild to Moderate Ulcerative Colitis","Efficacy and Safety of Two-step Acupuncture Therapy for Symptom Relief in Adults with Mild to Moderate Ulcerative Colitis","Inclusion Criteria:\n\nEligible participants are those aged 18 to 70 years who meet the diagnostic criteria for mild to moderate UC, have a PRO2 score of ≥ 2 points, and provide written informed consent. Patients currently receiving oral and\u002For topical 5-aminosalicylic acid (such as mesalamine) may continue their treatment during the study period.\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Diagnosis of Crohn's disease, intestinal tuberculosis, chronic intestinal infections, or intestinal malignancies.\n2. Current treatment with corticosteroids, thiopurines, biologics, or oral small molecules.\n3. Severe skin conditions or infections.\n4. Presence of severe underlying medical conditions, including but not limited to cardiovascular diseases, hepatobiliary diseases, kidney diseases, hematologic disorders, autoimmune diseases, communicable diseases, severe malnutrition, or malignancies.\n5. Mental illness, cognitive dysfunction, or language disorders.\n6. Receipt of acupuncture therapy for UC within the past month.\n7. Substance abuse issues.\n8. Pregnancy, plans to become pregnant within the next year, lactation, or being within 12 months postpartum.",{"count":540,"type":22},64,[58],"Ulcerative colitis (UC) is one of the two primary forms of inflammatory bowel disease. This condition is characterized by continuous mucosal inflammation that begins in the rectum and extends proximally throughout the colon. Common intestinal symptoms also include rectal bleeding, increased stool frequency, tenesmus, nocturnal bowel movements, and crampy abdominal pain. Acupuncture has been suggested as a potential intervention to alleviate clinical symptoms of UC. This single-center, parallel-group, two-arm, randomized, sham-controlled trial aims to evaluate the effects and safety of acupuncture for UC.",[544],"Ulcerative Colitis",[87,546,547,548,480],"Ulcerative colitis","Patient-reported outcome 2","Inflammatory bowel disease","2024-09-24",{"date":551,"type":38},"2024-09-27",{"date":553,"type":22},"2024-11-01",{"date":555,"type":22},"2026-10-31",{"name":44,"class":45},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":578},"100556300","electroacupuncture-treatment-of-behavioral-and-psycological-symptoms-in-patients-with-alzheimers-disease-100556300","NCT06523309","Electroacupuncture Treatment of Behavioral and Psycological Symptoms in Patients With Alzheimer's Disease","Prospective Registry of Electroacupuncture Treatment for Patients With Different Behavioral and Psycological Symptoms of Alzheimer's Disease","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for AD in the NIA-AA standard;\n2. Clinical dementia rating scale ≤2 points;\n3. Accompanied by at least one psychobehavioral symptom, NPI：frequency × degree ≥1 point;\n4. Sign informed consent.\n\nExclusion Criteria:\n\n1.There are contraindications for acupuncture treatment, such as the tendency of acupoint bleeding or allergy to metal",{"count":565,"type":22},1000,"This study aims to establish a prospective case registration research platform for electroacupuncture in treating behavioral and psychological symptoms in patients with mild to moderate Alzheimer's disease, and to investigate the dose-effect relationship and cost-effectiveness of electroacupuncture for these symptoms.",[568,569],"BPSD (Behavioral and Psycological Symptoms of Dementia)","Alzheimer's Dementia","2024-07-25",{"date":572,"type":38},"2024-07-26",{"date":574,"type":22},"2024-07-30",{"date":576,"type":22},"2027-10-31",{"name":44,"class":45},7,{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":78,"minAge":496,"maxAge":54,"enrollmentInfo":587,"targetDuration":4,"studyType":23,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":601,"locationsCount":46},"100484239","effect-of-electroacupuncture-on-benign-prostatic-hyperplasia-100484239","NCT05585450","Effect of Electroacupuncture on Benign Prostatic Hyperplasia","Effect of Electroacupuncture on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: a Randomized Controlled Trial","EABPH","Inclusion Criteria:\n\n1. Diagnosis of BPH in accordance with the European Association of Urology (EAU) guideline;\n2. Male participants aged between 40 and 80 years;\n3. Lower urinary tract symptoms (LUTS) for at least three months;\n4. IPSS total score ≥8;\n5. Prostate volume ≥20 mL;\n6. Urinary peak flow rate (Qmax) ≤15 mL\u002Fs;\n7. Voluntary participation in the trial and signed written informed content.\n\nExclusion Criteria:\n\n1. Post-void residual urine volume (PVR) ≥150 mL;\n2. Acute urinary retention or catheterization for outflow obstruction within the 3 months (Except for post-surgical disposable catheterization);\n3. Prostate cancer or prostate-specific antigen (PSA) level ≥4.0 ng\u002FmL;\n4. Neurogenic lower urinary tract dysfunction; prostatitis; uncontrolled symptomatic urinary tract infections; urethral strictures; bladder diverticula; bladder stones; bladder cancer; history of genitourinary system surgery (prostate, bladder, urethra, etc.);\n5. Previous acupuncture treatment for BPH in the preceding one month, or α-blockers, 5α-reductase inhibitor, muscarinic receptor antagonists, or any other specific medication usage in the previous two weeks unless a stable 5α-reductase inhibitor usage of over three months;\n6. Severe lung, heart, liver, kidney, metabolic, or mental illness, coagulation dysfunction, or with obvious cognitive dysfunction;\n7. Installed cardiac pacemaker, allergy to metal, severe fear of acupuncture or unbearable to the stimulation of EA.",{"count":588,"type":22},306,[58],"The study aims to assess the efficacy and safety of electroacupuncture among men with benign prostatic hyperplasia (BPH), compared with sham electroacupuncture.",[592],"Benign Prostatic Hyperplasia",[201,202,594],"lower urinary tract symptoms","2024-07-17",{"date":597,"type":38},"2024-07-18",{"date":599,"type":38},"2023-03-09",{"date":512,"type":22},{"name":44,"class":45},""]